Re: Routine Consumption of Aspirin to Prevent Heart Attacks and Strokes "A Big Lie"
- From: "trigonometry1972@xxxxxxxxx |" <trigonometry1972@xxxxxxxxx>
- Date: Tue, 29 Sep 2009 23:39:05 -0700 (PDT)
On Sep 29, 7:34 pm, "trigonometry1...@xxxxxxxxx |"
<trigonometry1...@xxxxxxxxx> wrote:
On Sep 28, 9:15 am, Roman Bystrianyk <rbystria...@xxxxxxxxx> wrote:
On Sep 28, 9:55 am, "D. C. Sessions" <d...@xxxxxxxxxxxxxxxx> wrote:
In message <e569672d-b092-48e6-b521-36044cc37...@xxxxxxxxxxxxxxxxxxxxxxxxxxxx>, PeterB wrote:
And yet (many, large) randomized, placebo-controlled studies show
lower rates of ischemic events and deaths with aspirin and other
clotting inhibitors.
Of course, none of those studies happened because aspirin can't be
patented.
You may find this of interest. Enjoy your day.
Aspirin Risks In Healthy Individuals
http://www.healthsentinel.com/joomla/index.php?option=com_content&vie....
Felix Hoffman at Bayer Industries synthesized aspirin over 100 years
ago. Today there have been many ads promoting aspirin’s potential to
reduce the risk of heart attack and stroke in certain people. However,
the decision to use aspirin as a preventative is not as simple as it
looks. What generally has not been analyzed are the risks and costs
associated with aspirin therapy.
In the January issue of The Annals of Pharmacotherapy the authors
analyze the lifetime cumulative risk, the potential negative effects
on quality-adjusted-life-years (QALYs), life expectancy, and cost of
aspirin therapy. The authors construct a model of healthy individuals
starting at age 50 taking a 325 mg enteric-coated daily aspirin. Based
on numerous references the authors take into account adverse effects
such as upper gastrointestinal bleeding, quality of life factor, and
aspirin cost.
Based on their analysis, aspirin therapy only had a modest negative
effect on both QALYs and life expectancy. The average lifetime cost
was determined to be $460 per person.
However, the authors found that, “for every 15 healthy 50-year-old men
started on aspirin therapy, one will have a complication in his
lifetime; for every 556 individuals started on aspirin therapy, one
will die from complications.” Comparison of death risk of lifetime
aspirin therapy (1 in 556) versus other mortality risks were listed as
follows: hip surgery (1 in 345), cardiac catheterization (1 in 500),
general anesthesia (1 in 3,685), annual accidents (1 in 3,014), food
poisoning (1 in 56,424), sky diving (1 in 70,130 per dive), and yearly
driving with a cell phone (1 in 76,900).
The authors also note that, “starting aspirin at an earlier age
resulted in a larger absolute reduction in both QALYs and life
expectancy, increased cost, and not surprisingly, a greater number of
complications.”
The authors also analyzed the use of proton pump inhibitors (PPIs) to
reduce the aspirin risk. They determined a modest increase in quality
of life and life expectancy, and a decreased risk in major and
intermediate GI (gastrointestinal) bleeds by 50%, but at a substantial
increase in cost. The addition of PPIs resulted in an increase from an
average lifetime cost of $460 per person to $18,400.
The authors do not attempt to incorporate any of the potential
benefits of aspirin. On the contrary, as the aim of the study was to
determine the risk, all complication rates attributable to aspirin
from numerous scientific sources were utilized. The authors note that,
“although good published data exist to accurately model the drawbacks
of aspirin therapy, the benefits of aspirin in cancer chemoprevention
are preliminary at best and will likely not be apparent for at least
10 years of aspirin therapy. Short-term data for the efficacy of
aspirin for the prevention of primary coronary events exist, but long-
term data are currently unavailable.”
Source: The Annals of Pharmacotherapy, January 2005
PPI meds have long term risks. Ranging from gastric atrophy,
pneumonia by way of aspirated microflora from
a microflora colonized stomach because of too little stomach
acid, neurological damage and symptoms,
dyspepsia, weaken bones, dental decay, and prostate
problems among other things.
Though the idea is low dose aspirin is so the that GI damage may not
be as bad as from a higher dosage or so it was hoped.
And there is the additional problem that aspirin may prevent
clots and related infarcts at the cost of more hemorrhage type
strokes.
Trig
I should add that even some mainline sources admit for
primary prevention of CVD events the value of aspirin is uncertain.
Lancet. 2009 May 30;373(9678):1849-60.
<snip>
Aspirin in the primary and secondary prevention
of vascular disease: collaborative meta-analysis
of individual participant data from randomised
trials.
<snip>
CTSU, Oxford University, Oxford, UK. ,
<snip>
..
INTERPRETATION: In primary prevention without
previous disease, aspirin is of uncertain net value
as the reduction in occlusive events needs to
be weighed against any increase in major bleeds.
Further trials are in progress.
FUNDING: UK
Medical Research Council, British Heart Foundation,
Cancer Research UK, and the European Community
Biomed Programme.
PMCID: PMC2715005
PMID: 19482214
.
- References:
- Re: Routine Consumption of Aspirin to Prevent Heart Attacks and Strokes "A Big Lie"
- From: Roman Bystrianyk
- Re: Routine Consumption of Aspirin to Prevent Heart Attacks and Strokes "A Big Lie"
- From: trigonometry1972@xxxxxxxxx |
- Re: Routine Consumption of Aspirin to Prevent Heart Attacks and Strokes "A Big Lie"
- Prev by Date: Re: A bunch of blatant liars here don't know when to shut up
- Next by Date: forex
- Previous by thread: Re: Routine Consumption of Aspirin to Prevent Heart Attacks and Strokes "A Big Lie"
- Next by thread: Re: Routine Consumption of Aspirin to Prevent Heart Attacks and Strokes "A Big Lie"
- Index(es):
Relevant Pages
|
